Peptron
Financials
Valuation Metrics
Peptron's Market Cap is ₩2.2T. At end of 2025 it was ₩5.9T. Ranked #181 of 2,405 in KR market (top 8%), #28 of 1,627 on KOSDAQ (top 2%), #14 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 6%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 2.20T KRW | KR#181/2,405 Sec#14/231 |
| Revenue | 6.00B KRW | KR#2,309/2,405 Sec#188/231 |
| Net Income | -20.53B KRW | KR—/2,405 Sec—/231 |
| Total Assets | 167.98B KRW | KR#1,426/2,405 Sec#109/231 |
| Net Assets | 129.48B KRW | KR#1,238/2,405 Sec#95/231 |
| Employees | 112 | KR#1,553/2,405 Sec#121/231 |
| Value | ||
| P/B | 16.98x | KR#2,386/2,405 Sec#223/231 |
| P/S | 366.42x | KR#2,391/2,405 Sec#222/231 |
| FCF Yield | -1.05% | KR—/2,405 Sec—/231 |
| Profitability | ||
| ROE | -15.86% | KR#2,029/2,405 Sec#156/231 |
| ROA | -12.22% | KR#2,139/2,405 Sec#163/231 |
| Op. Margin | -427.48% | KR#2,344/2,405 Sec#202/231 |
| Revenue Growth | 15.87% | KR#652/2,405 Sec#60/231 |
| Financial Health | ||
| Debt Ratio | 29.74% | KR#584/2,405 Sec#67/231 |
| Total Debt | 30.28B KRW | KR#1,220/2,405 Sec#94/231 |
| FCF | -23.08B KRW | KR#1,920/2,405 Sec#186/231 |
| Cash | 12.31B KRW | KR#1,568/2,405 Sec#129/231 |
| Current Ratio | 9.11x | KR#118/2,405 Sec#28/231 |
| Performance | ||
| 1Y Return | -65.14% | KR#2,216/2,405 Sec#209/231 |
| 1M Return | -27.18% | KR#2,155/2,405 Sec#213/231 |
| From 52W High | -75.97% | KR#2,208/2,405 Sec#199/231 |
| 1Y MDD | -78.52% | KR#2,243/2,405 Sec#198/231 |
| Trading | ||
| Volume | 98,884 shares | KR#635/2,405 Sec#64/231 |
| Trading Value | 9.40B KRW | KR#208/2,405 Sec#14/231 |
| Foreign Own. | 4.60% | KR#926/2,405 Sec#82/231 |
| Per Share | ||
| EPS | -881 KRW | KR—/2,405 Sec—/231 |
| BPS | 5,553 KRW | KR#1,424/2,405 Sec#102/231 |
Company Info
Peptron, established in 1997 for biotechnology advanced material manufacturing and pharmaceutical R&D, was listed on KOSDAQ in 2015. The company develops pharmaceuticals based on peptide engineering and drug efficacy sustaining original technology, securing clinical trial and commercialization capabilities through GMP mass production facilities. With its SmartDepot technology, Peptron can develop various pharmaceuticals, accelerate its contract drug development and manufacturing business, and conduct research on metabolic disease treatments and anticancer drugs. The company is headquartered in Yuseong-gu, Daejeon.